Acutus Medical, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OTC.Pink
Acutus Medical's Q3 2024 results show a significant increase in revenue driven by its manufacturing agreement with Medtronic, despite continued losses from discontinued operations.
OTC.Pink
10-Q: Acutus Medical Reports Q2 2024 Results, Revenue Increases Significantly Following Strategic Shift
Acutus Medical's Q2 2024 results show a significant increase in revenue due to its strategic shift to manufacturing for Medtronic, despite continued losses.
OTC.Pink
Acutus Medical's Q1 2024 results reflect a strategic realignment towards manufacturing for Medtronic, alongside a Nasdaq delisting and a shift to OTC trading.